REPLY
The pandemic has accelerated the trend of adopting new interfaces in both consumer and professional fields, according to Reply’s new research “New Interfaces, Zero Interfaces” , based on Reply’s Trend SONAR proprietary data-driven platform.
The research explores the development prospects of state-of-the-art interfaces that are coming to prominence in this new normal by analysing significant studies, scientific articles and patents published in the last two years, while integrating them with relevant experiences from Reply customers.
Smartphones and their operating systems have been enabling completely new experiences for almost 15 years; now 5G, high-speed connectivity, and edge computing are set to provide a further boost for user interface technologies like wearables, smart speakers, 3D spatial interfaces, multimodal and brain-computer interfaces.
“Companies will develop more personalized and emotional interactions with customers, as well as new possibilities for the analysis and visualization of information,” commented Filippo Rizzante, CTO Reply. "Looking at the impacts of the pandemic on the interfaces we use today, there are two trends that more than others we are seeing growing: a wider demand for remote healthcare, and the need to reduce touch interfaces".
Voice is the fastest growing interface, thanks to its frequent use in daily life through smart speakers and cars. It is also increasingly being used for marketing purposes, allowing popular brands to literally speak directly to consumers – a much more intimate connection than the ones offered by traditional touchpoints.
Industries like pharmaceuticals, fashion, real estate, and travel are progressively implementing extended reality technologies through mobile apps or special headsets. Extended Reality is set to greatly enhance training and workplace collaboration, offering teams much better ways of meeting and sharing ideas and thoughts in both virtual and augmented realities.
Wearables are becoming steadily more relevant in the field of daily-use interfaces. Rings, glasses, and ‘hearables’ can be connected to smart assistants to help with daily life and monitor behaviour. Combined with next-gen smartwatches, these kind of wearables could become the first full-alternative, independent, consumer-ecosystem to the smartphone.
Gaze control and eye tracking will allow people to control, communicate and interact with machines based on eye movement patterns, fixations and pupil reaction. Brain-computer interface (BCI) technology is accelerating as well. The focus is still predominantly medical and scientific, however its diffusion into other areas is increasing, blurring the lines between computing and biology.
In the mobility industry , new interfaces will have a crucial role in the safety and the security of vehicle drivers and pedestrians, using new smart technologies to improve safety and communications with other road users. New interfaces will also make cars and trucks more customisable and predictive. Moreover, autonomous driving will enable greater development in entertainment and advertising within vehicles.
Retail-related interface development is experiencing seismic shifts as well, helping shoppers enjoy the benefits of physical shopping – tactile, sensory and social – in digital virtual spaces that enable frictionless and comfortable shopping while driving customer acquisition, retention and loyalty to new heights. The use of Artificial Intelligence-based and conversational interfaces will refine customisation down to the needs of the individual customer. AI and digital technologies allow for more personalisation for customers, from inspiration to tackling sizing and fitting issues in fashion retail.
With increasing sensor integration and natural embedding into the surrounding world, interfaces will be invisibly interwoven into everyday life and work environments, turning anything into an interface, seamlessly communicating with each other and expanding human cognition and senses.
For more insights download the full research “New Interfaces, Zero Interfaces” . This new research is part of the Reply Market Research series, including the recent “From Cloud to Edge” and “Rebooting Longevity” .
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005065/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom